Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The autosomal codominant genetic disorder alpha-1 antitrypsin (AAT) deficiency (AATD) causes pulmonary and liver disease. Individuals homozygous for the mutant Z allele accumulate polymers of Z-AAT protein in hepatocytes, where AAT is primarily produced. This accumulation causes endoplasmic reticulum (ER) stress, oxidative stress, damage to mitochondria, and inflammation, leading to fibrosis, cirrhosis, and hepatocellular carcinoma. The magnitude of AAT reduction and duration of response from first-generation intravenously administered RNA interference (RNAi) therapeutic ARC-AAT and then with next-generation subcutaneously administered ARO-AAT were assessed by measuring AAT protein in serum of the PiZ transgenic mouse model and human volunteers. The impact of Z-AAT reduction by RNAi on liver disease phenotypes was evaluated in PiZ mice by measuring polymeric Z-AAT in the liver; expression of genes associated with fibrosis, autophagy, apoptosis, and redox regulation; inflammation; Z-AAT globule parameters; and tumor formation. Ultrastructure of the ER, mitochondria, and autophagosomes in hepatocytes was evaluated by electron microscopy. In mice, sustained RNAi treatment reduced hepatic Z-AAT polymer, restored ER and mitochondrial health, normalized expression of disease-associated genes, reduced inflammation, and prevented tumor formation. RNAi therapy holds promise for the treatment of patients with AATD-associated liver disease. ARO-AAT is currently in phase II/III clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“data were analyzed using the comparative CT method of relative quantification (43).”
MethodInflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443 · cited 1×
“RNAi is a naturally occurring process by which cells cleave mRNA hybridized to the complementary antisense strand of a small interfering RNA or synthetic RNAi trigger (23).”
BackgroundKamimoto, T., Shoji, S., Hidvegi, T., Mizushima, N., Umebayashi, K., Perlmutter, D. H., & Yoshimori, T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509409200 · Cited by 259 · cited 1×
“Incompletely folded and polymeric Z-AAT proteins in the liver are degraded by ER associated degradation (ERAD) and by autophagy (2, 18-20).”
BackgroundTurner, A. M., Stolk, J., Bals, R., Lickliter, J. D., Hamilton, J., Christianson, D. R., Given, B. D., Burdon, J. G., Loomba, R., Stoller, J. K., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.012 · Cited by 67 · cited 4×
“Approximately 90% of endogenous AAT in humans and in NHPs is believed to be hepatocyte produced, based on the maximum endogenous AAT reductions we have observed (25).”
BackgroundSelf-citation
Cited by
Therapeutic siRNA: State-of-the-Art and Future Perspectives
Friedrich, M., & Aigner, A. (2022) · BioDrugs · doi:10.1007/s40259-022-00549-3 · Cited by 396
O’Brien, M. E., Murray, G., Gogoi, D., Yusuf, A., McCarthy, C., Wormald, M. R., Casey, M., Gabillard-Lefort, C., McElvaney, N. G., & Reeves, E. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052441 · Cited by 91
Hepatocyte targeting via the asialoglycoprotein receptor
Ramírez-Cortés, F., & Ménová, P. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00652f · Cited by 55
GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases
Qin, Z.-X., Zuo, L., Zeng, Z., Ma, R., Xie, W., Zhu, X., & Zhou, X. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2466767 · Cited by 32
“This platform’s trivalent GalNAc ligands are based on γ-glutamyl dipeptide, similar to the YEE-GalNAc ligand, currently advancing into late-stage clinical trials for liver diseases associated with alpha-1 antitrypsin (AAT) [113,114].”
Brzozowska, N., Wu, L. Y. D., Khodzhaeva, V., Griffiths, W. J., Duckworth, A., Jung, H., Coorens, T. H. H., Hooks, Y., Chambers, J. E., Campbell, P. J., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02125-1 · Cited by 11
“Although therapies based on liver-directed RNA interference, suppressing the expression of Z-A1AT, have shown promise in mouse models 26 and preliminary human trials 27 , targeted blockade or deletion of the C-terminus of A1AT may represent an alternative strategy for the suppression of polymer…”
Metadata
- Authors
- Wooddell, C. I., Blomenkamp, K., Peterson, R. M., Subbotin, V. M., Schwabe, C., Hamilton, J., Chu, Q., Christianson, D. R., Hegge, J. O., Kolbe, J., Hamilton, H. L., Branca-Afrazi, M. F., Given, B. D., Lewis, D. L., Gane, E., Kanner, S. B., & Teckman, J. H.
- Venue
- JCI Insight
- Published
- 2020-06-18
- Volume
- 5
- Issue
- 12
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W3023605248
- Cited by
- 60
- References
- 5
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.